id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-308095-mehmk49a	Marks, Jonathan H.	Lessons from Corporate Influence in the Opioid Epidemic: Toward a Norm of Separation	2020-07-13		.txt	text/plain	10670	449	46	Opioid companies built these webs as part of corporate strategies of influence that were designed to expand the opioid market from cancer patients to larger groups of patients with acute or chronic pain, to increase dosage as well as opioid use, to downplay the risks of addiction and abuse, and to characterize physicians' concerns about the addiction and abuse risks as "opiophobia." In the face of these pervasive strategies, conflict of interest policies have proven insufficient for addressing corporate influence in medical practice, medical research, and public health policy. The focus on "naming and shaming" individuals, even when warranted, threatens to downplay or ignore a systemic problem: institutional and societal cultures and practices that embrace partnership with industry and, wittingly or unwittingly, promote companies' products, increase brand loyalty, burnish corporate reputations, defuse support for the regulation of companies' products and marketing practices, and reinforce the framing of public health problems and their solutions in ways that are least threatening to the commercial interests of those companies (Marks 2019a) .	./cache/cord-308095-mehmk49a.txt	./txt/cord-308095-mehmk49a.txt